Exposure-response and age subgroup analyses to support body-weight (BW) dosing of brentuximab vedotin (BV) in newly diagnosed high-risk classical Hodgkin lymphoma (cHL) in children and young adults (aged 2-21 years [y]): A randomized children's oncology group phase 3 trial (AHOD1331)

Category Primary study
JournalCANCER RESEARCH
Year 2023
This article has no abstract
Epistemonikos ID: c7ae83c14cbac76dbde78d27f36c8b19b01d4080
First added on: Feb 16, 2024